Friday's Underperforming Sectors: General Contractors & Builders, Healthcare Providers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 28 2025
0mins
Should l Buy AGL?
Source: NASDAQ.COM
Market Performance: Hospital and medical practitioners' shares are lagging the market, down approximately 0.2% overall.
Key Contributors: Ardent Health and Agilon Health are leading the decline, with shares down 2.8% and 1.8%, respectively.
Sector Laggards: The report also mentions general contractors and builders as part of the sector laggards on the same day.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.377
Low
0.88
Averages
0.88
High
0.88
Current: 0.377
Low
0.88
Averages
0.88
High
0.88
About AGL
agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Agilon Health for violations of securities laws, concerning securities purchases between February 26, 2025, and August 4, 2025, with a deadline for participation set for March 2, 2026.
- False Statement Allegations: The complaint alleges that Agilon Health made false and misleading statements, overstating the impact of its strategic actions, which led to investor losses when the truth emerged, highlighting significant failures in the company's disclosure practices.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who do not act may become absent class members, potentially jeopardizing their claims.
- Investor Rights Protection: The Schall Law Firm specializes in securities class actions and encourages affected investors to reach out to discuss their rights, demonstrating a commitment to protecting investor interests.
See More
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating agilon health for potential securities violations related to trades made between February 26 and August 4, 2025, urging investors to apply as lead plaintiffs in a class action by the March 2, 2026 deadline to protect their rights.
- Financial Guidance Missteps: The company is accused of issuing unrealistic financial guidance for 2025 without adequately disclosing significant industry challenges, resulting in a 51.5% stock price drop on August 5, 2025, after the true situation was revealed, causing substantial investor losses.
- False Statement Allegations: The lawsuit claims that agilon and its executives made false and misleading statements in financial reports, failing to disclose the actual impact of their “strategic actions” on financial performance, which severely affected investor decision-making.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information, including former employees and shareholders, to contact them to support the investigation into agilon health, ensuring that investors' legal rights are upheld.
See More
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Agilon Health, encouraging those who purchased AGL shares between February 26, 2025, and August 4, 2025, to contact the firm regarding possible lead plaintiff appointment for potential recovery.
- Allegations of False Statements: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose significant industry headwinds that would impact their 2025 guidance, misleading shareholders about the company's prospects.
- Overstated Financial Impact: Defendants are accused of materially overstating the immediate positive financial impact of strategic actions taken by Agilon, which misled shareholders and harmed their investment decisions.
- Registration Deadline: Shareholders must register by March 2, 2026, to participate in the class action, and upon registration, they will receive status updates throughout the case lifecycle, ensuring their rights are protected.
See More
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors that class action lawsuits have been filed against companies including agilon health, Fermi Inc., Varonis Systems, and Ardent Health, with deadlines for lead plaintiff motions approaching.
- agilon health Allegations: From February 26 to August 4, 2025, agilon health is accused of making materially false statements regarding its financial guidance, failing to disclose industry headwinds, which misled investors about the company's prospects, with a lead plaintiff deadline of March 2, 2026.
- Fermi Inc. Lawsuit Details: Fermi Inc. is charged with overstating tenant demand and the reliance on a single tenant's funding for its Project Matador from October 1 to December 11, 2025, with a lead plaintiff deadline of March 6, 2026.
- Varonis and Ardent Issues: Varonis is accused of being ill-equipped to sustain its ARR growth from February 4 to October 28, 2025, while Ardent is charged with failing to accurately assess the collectability of accounts receivable from July 18, 2024, to November 12, 2025, with lead plaintiff deadlines of March 9, 2026, for both companies.
See More
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Agilon Health, Inc. on behalf of investors who purchased securities between February 26, 2025, and August 4, 2025, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Allegation Details: The lawsuit claims that Agilon executives issued unrealistic 2025 financial guidance despite being aware of significant industry challenges, and materially overstated the positive financial impact of their strategic actions, leading to a severely distorted view of the company's business and prospects among investors.
- Investor Rights: Affected investors must apply by March 2, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for more information.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, boasting extensive litigation experience and a nationwide practice.
See More
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Agilon Health (NYSE: AGL) securities between February 26, 2025, and August 4, 2025, alleging the company failed to disclose significant risks to its business prospects.
- Misleading Financial Guidance: The complaint alleges that Agilon Health issued optimistic financial guidance for 2025 despite being aware of substantial industry headwinds, misleading investors and overstating the positive impact of strategic actions taken to mitigate risks.
- Executive Departure Impact: On August 4, 2025, Agilon announced the resignation of CEO Steven Sell, and the subsequent disappointing financial results led to a stock price drop of over 50% to close at $0.8801 on August 5, 2025, significantly impacting investor confidence.
- Call to Action for Shareholders: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by March 2, 2026, while those who choose not to participate can remain absent class members and still retain their rights to recovery.
See More




